

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1-65. (Canceled)

66. (Currently amended) A composition comprising:

A) a reversed cubic liquid crystalline phase ~~or a reversed hexagonal liquid crystalline phase~~ structured fluid, ~~or combinations thereof~~, comprising:

i) water;

ii) phospholipid; and

iii) one or more essential oils or components thereof, and

B) a pharmaceutical active solubilized in said structured fluid to a higher concentration than would be possible in the same composition from which said one or more essential oils or components thereof is absent, wherein said ~~compound~~ pharmaceutical active is otherwise less than 5% by weight soluble in soybean oil.

67. (Currently amended) A composition comprising:

A) a reversed cubic liquid crystalline phase ~~or a reversed hexagonal liquid crystalline phase~~ structured fluid, ~~or combinations thereof~~, comprising:

i) water;

ii) phospholipid; and

iii) tocopherol, and

B) a pharmaceutical active solubilized in said structured fluid to a higher concentration than would be possible in the same composition from which said tocopherol is absent, wherein said compound is otherwise less than 5% by weight soluble in soybean oil.

68. (Currently amended) An internally administrable solvent system comprising a reversed cubic liquid crystalline phase ~~or a reversed hexagonal liquid crystalline phase~~ structured fluid which exists at body temperature and ~~or combinations thereof~~, in which an effective amount of a

~~compound~~ pharmaceutical active may be incorporated, wherein said ~~compound~~ pharmaceutical active is ~~otherwise~~ less than 5% by weight soluble in soybean oil, said solvent system formed from

a. water,

b. phospholipid, and

c. one or more essential oils or components thereof, or tocopherol, or a mixture thereof,

wherein said pharmaceutical active may be incorporated to a higher concentration than would be possible in the same composition from which said one or more essential oils or components thereof or tocopherol or mixture thereof is absent.

69. (Canceled)

70. (New) The composition of claim 66, wherein a ratio of said phospholipid to essential oils or components thereof in said structured fluid is from 0.5:1 to 1.5:1.

71. (New) The composition of claim 70, wherein said ratio of said phospholipid to essential oils or components thereof in said structured fluid is from 0.7:1 to 1.2:1.

72. (New) The composition of claim 66, wherein said pharmaceutical active is greater than 5% soluble in said essential oil.

73. (New) The composition of claim 66, wherein said composition is suitable for injection.

74. (New) The composition of claim 66, wherein said pharmaceutical active is a therapeutic agent selected from the group consisting of analgesics, anesthetics, antibiotics, antifungals, antineoplastic agents, antiviral agents, enzyme inhibitors, hormones, anticonvulsants, immunosuppressants, antipsychotics and tumor necrosis factor (TNF) inhibitors.

75. (New) The composition of claim 66, wherein said pharmaceutical active is selected from the group consisting of buprenorphine, chloramphenicol, cyclosporin A, daunorubicin, erythromycin A, fentanyl, nitrazepam, SN-38, irinotecan and bupivacaine.

76. (New) The composition of claim 66, wherein said essential oil is selected from the group consisting of spearmint, ginger, clovebud, eucalyptus, peppermint, anise seed, balsam of Peru, coriander, orange and santalwood.

77. (New) The composition of claim 67, wherein a ratio of said phospholipid to said tocopherol is from 0.5:1 to 1.5:1.

78. (New) The composition of claim 77, wherein said ratio of said phospholipid to said tocopherol is from 0.7:1 to 1.2:1.

79. (New) The composition of claim 67, wherein said pharmaceutical active is greater than 5% soluble in said tocopherol.

80. (New) The composition of claim 67, wherein said composition is suitable for injection.

81. (New) The composition of claim 67, wherein said pharmaceutical active is selected from a therapeutic group consisting of analgesics, anesthetics, antibiotics, antifungals, antineoplastic agents, antiviral agents, enzyme inhibitors, hormones, anticonvulsants, immunosuppressants, antipsychotics and tumor necrosis factor (TNF) inhibitors.

82. (New) The composition of claim 67, wherein said pharmaceutical active is selected from the group consisting of buprenorphine, chloramphenicol, cyclosporin A, daunorubicin, erythromycin A, fentanyl, nitrazepam, SN-38, irinotecan and bupivacaine.

83. (New) The composition of claim 68, wherein a ratio of said phospholipid to said one or more essential oils or components thereof, or tocopherol or a mixture thereof is from 0.5:1 to 1.5:1.

84. (New) The composition of claim 83, wherein said ratio of said phospholipid to said one or more essential oils or components thereof, or tocopherol or a mixture thereof is from 0.7:1 to 1.2:1.

85. (New) The composition of claim 68, wherein said pharmaceutical active is equal to or greater than 5% soluble in said one or more essential oils or components thereof, or tocopherol or a mixture thereof.

86. (New) The composition of claim 68, wherein said composition is suitable for injection.

87. (New) The composition of claim 68, wherein said pharmaceutical active is selected from a therapeutic group consisting of analgesics, anesthetics, antibiotics, antifungals, antineoplastic agents, antiviral agents, enzyme inhibitors, hormones, anticonvulsants, immunosuppressants, antipsychotics and tumor necrosis factor (TNF) inhibitors.

88. (New) The composition of claim 68, wherein said pharmaceutical active is selected from the group consisting of buprenorphine, chloramphenicol, cyclosporin A, daunorubicin, erythromycin A, fentanyl, nitrazepam, SN-38, irinotecan and bupivacaine.

89. (New) The composition of claim 68, wherein said essential oil is selected from the group consisting of spearmint, ginger, clovebud, eucalyptus, peppermint, anise seed, balsam of Peru, coriander, orange and santalwood.

90. (New) The composition of claim 66, wherein said phospholipid comprises phosphatidylcholine.

91. (New) The composition of claim 67, wherein said phospholipid comprises phosphatidylcholine.

92. (New) The composition of claim 68, wherein said phospholipid comprises phosphatidylcholine.

93. (New) The composition of claim 67, wherein said tocopherol is alpha- tocopherol.

94. (New) The composition of claim 68, wherein said tocopherol is alpha- tocopherol.

95. (New) The composition of claim 66, wherein said reversed cubic liquid crystalline phase is bicontinuous.

96. (New) The composition of claim 67, wherein said reversed cubic liquid crystalline phase is bicontinuous.

97. (New) The composition of claim 68, wherein said reversed cubic liquid crystalline phase is bicontinuous.

98. (New) A composition comprising:

A) a reversed cubic liquid crystalline phase structured fluid, comprising:

- i) water;
- ii) phospholipid;
- iii) an essential oil or component thereof, and

B) a pharmaceutical active that is less than 5% by weight soluble in soybean oil solubilized in said structured fluid.

99. (New) A composition comprising:

A) a reversed cubic liquid crystalline phase structured fluid, comprising:

- i) water;
- ii) phospholipid;
- iii) tocopherol, and

B) a pharmaceutical active that is less than 5% by weight soluble in soybean oil solubilized in said structured fluid.

100. (New) A composition comprising:

A) a reversed cubic liquid crystalline phase structured fluid, comprising:

- i) water;
- ii) phospholipid;

iii) one or more essential oils or components thereof or tocopherol or a mixture thereof,
and

B) a pharmaceutical active that is less than 5% by weight soluble in soybean oil solubilized in said structured fluid.

101. (New) A reversed cubic liquid crystalline phase structured fluid which exists at body temperature, comprising:

i) water;

ii) phospholipid; and

iii) one or more essential oils or components thereof or tocopherol or a mixture thereof,

wherein a pharmaceutical active that is less than 5% by weight soluble in soybean oil can be solubilized in said reversed cubic liquid crystalline phase structured fluid.

102. (New) An internally administrable solvent system comprising a reversed cubic liquid crystalline phase structured fluid in which an effective amount of a pharmaceutical active may be incorporated, wherein said pharmaceutical active is less than 5% by weight soluble in soybean oil, said solvent system formed from

a. water,

b. phospholipid, and

c. one or more essential oils or components thereof, or tocopherol, or a mixture thereof,

wherein said pharmaceutical active may be incorporated to a higher concentration than would be possible in the same composition from which said one or more essential oils or components thereof or tocopherol or mixture thereof is absent, and

wherein a ratio of said phospholipid to essential oils or components thereof or tocopherol in said structured fluid is from 0.5:1 to 1.5:1.

103. (New) A reversed cubic liquid crystalline phase structured fluid, comprising:

i) water;

ii) phospholipid; and

iii) one or more essential oils or components thereof or tocopherol or a mixture thereof,

wherein a pharmaceutical active that is less than 5% by weight soluble in soybean oil can be solubilized in said reversed cubic liquid crystalline phase structured fluid, and

wherein a ratio of said phospholipid to essential oils or components thereof or tocopherol in said structured fluid is from 0.5:1 to 1.5:1.

104. (New) The composition of claim 66 wherein said pharmaceutical active, in the absence of said reversed cubic liquid crystalline phase, requires more than 100 ml of water to solubilize a single therapeutic dose.

105. (New) The composition of claim 67 wherein said pharmaceutical active, in the absence of said reversed cubic liquid crystalline phase, requires more than 100 ml of water to solubilize a single therapeutic dose.

106. (New) The composition of claim 98 wherein said pharmaceutical active, in the absence of said reversed cubic liquid crystalline phase, requires more than 100 ml of water to solubilize a single therapeutic dose.

107. (New) The composition of claim 99 wherein said pharmaceutical active, in the absence of said reversed cubic liquid crystalline phase, requires more than 100 ml of water to solubilize a single therapeutic dose

108. (New) The composition of claim 66 wherein said reversed cubic liquid crystalline phase exists at body temperature.

109. (New) The composition of claim 67 wherein said reversed cubic liquid crystalline phase exists at body temperature.

110. (New) The composition of claim 98 wherein said reversed cubic liquid crystalline phase exists at body temperature.

111. (New) The composition of claim 99 wherein said reversed cubic liquid crystalline phase exists at body temperature.